{
    "paper_id": "1a74e4d2a615ae37ee0a3ae9bcf8af1688ca3f77",
    "metadata": {
        "title": "Diab\u00e8te et COVID-19 au nom du groupe de travail \"m\u00e9dicaments et COVID-19\" de la \"Soci\u00e9t\u00e9 Fran\u00e7aise de Pharmacologie et Th\u00e9rapeutique\"",
        "authors": [
            {
                "first": "B\u00e9atrice",
                "middle": [],
                "last": "Bouhanick",
                "suffix": "",
                "affiliation": {
                    "laboratory": "c Univ. Grenoble Alpes, Centre r\u00e9gional de pharmacovigilance de Grenoble CHU Grenoble",
                    "institution": "Universit\u00e9 Toulouse III",
                    "location": {
                        "addrLine": "UMR 1027",
                        "postCode": "31000, 38000",
                        "settlement": "Toulouse, Grenoble",
                        "country": "France, France"
                    }
                },
                "email": ""
            },
            {
                "first": "Jean-Luc",
                "middle": [],
                "last": "Cracowski",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Jean-Luc",
                "middle": [],
                "last": "Faillie",
                "suffix": "",
                "affiliation": {
                    "laboratory": "D\u00e9partement de pharmacologie m\u00e9dicale et toxicologie, Centre r\u00e9gional de pharmacovigilance Occitanie-Est",
                    "institution": "CHU",
                    "location": {
                        "addrLine": "Montpellier 371 avenue du Doyen Gaston Giraud",
                        "postCode": "34295",
                        "settlement": "Montpellier",
                        "country": "France. Adresse"
                    }
                },
                "email": ":jean-luc.faillie@umontpellier.fr"
            },
            {
                "first": "Au",
                "middle": [],
                "last": "Nom",
                "suffix": "",
                "affiliation": {},
                "email": ""
            }
        ]
    },
    "abstract": [
        {
            "text": "J o u r n a l P r e -p r o o f 2 R\u00e9sum\u00e9 D'apr\u00e8s les derni\u00e8res analyses de cas notamment en Chine et en Italie, le diab\u00e8te semble \u00eatre un facteur de risque d'aggravation de l'\u00e9tat clinique d'un patient atteint par le COVID-19 mais est-il un facteur de susceptibilit\u00e9 ? Une analyse de la litt\u00e9rature \u00e0 la date du 17 avril 2020 tente de r\u00e9pondre \u00e0 la question. Les donn\u00e9es concernant le type de traitement antidiab\u00e9tique sont tr\u00e8s rares. La dipeptidylpeptidase 4 (DPP-4), glycoprot\u00e9ine membranaire ubiquitaire pr\u00e9sente \u00e0 la surface de nombreuses cellules et existant aussi sous forme soluble, est impliqu\u00e9e dans les r\u00e9ponses immunitaires inflammatoires en modifiant la production de plusieurs cytokines. La DPP-4 est impliqu\u00e9e dans l'infection des cellules par certains virus. Nous abordons la question de l'utilisation des inhibiteurs des DPP-4 chez les patients diab\u00e9tiques. Une revue des recommandations sur la prise en charge des diab\u00e9tiques conclut ce travail.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "According to previous reports, diabetes seems to be associated with serious clinical events due to COVID-19. But is diabetes per se a risk factor of being infected by the virus? We discuss these points. Data about the antidiabetic drugs are scarce. Dipeptidylpeptidase-4 (DPP-4) is found as both a cell surface protein ubiquitously expressed in many tissues and as a soluble molecule found in serum/plasma, fluids. DPP-4 is involved in infection of cells by some viruses. We relate data about the use of DPP-4 inhibitors in diabetic patients. We conclude relating French and international recommendations in people with diabetes. glucose pouvant donner des mesures erron\u00e9es ou n'\u00e9tant pas valid\u00e9s en r\u00e9animation (free style libre fauss\u00e9 par de fortes doses de vitamines C et certains capteurs par le parac\u00e9tamol). La Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique (SFPT) a r\u00e9dig\u00e9 des questions/r\u00e9ponses sur le maniement des m\u00e9dicaments et le COVID accessibles \u00e0 tous [18]. Page 8 of 11 J o u r n a l P r e -p r o o f 8 La Soci\u00e9t\u00e9 am\u00e9ricaine du diab\u00e8te, en lien avec les Centers for Disease Control and",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "Prevention, propose un site d\u00e9di\u00e9 o\u00f9 sont r\u00e9pertori\u00e9s des conseils dans la gestion du traitement, les mesures barri\u00e8res pr\u00e9conis\u00e9es tandis qu'un blog quotidien est librement accessible [36].",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "R\u00e9f\u00e9rences",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        }
    ],
    "body_text": [
        {
            "text": "L'\u00e9pid\u00e9mie mondiale due au COVID-19 a fait \u00e9merger une litt\u00e9rature abondante sur les facteurs de risque associ\u00e9s \u00e0 sa survenue, tout patient n'\u00e9tant pas forc\u00e9ment symptomatique ou n'exprimant pas la maladie avec la m\u00eame gravit\u00e9. Le diab\u00e8te est rapidement devenu l'un des facteurs de risque potentiel mais qu'en est-il vraiment ? Le diab\u00e8te est-il un facteur de susceptibilit\u00e9 et/ou un facteur de gravit\u00e9 ? Dans ces circonstances, le traitement antidiab\u00e9tique et en particulier les inhibiteurs des DPP-4 pourrait-il jouer un r\u00f4le dans la survenue des infections ? C'est ce que nous nous proposons de relater ici.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Introduction"
        },
        {
            "text": "Il a \u00e9t\u00e9 sugg\u00e9r\u00e9 au d\u00e9part de l'\u00e9pid\u00e9mie de COVID-19 que le diab\u00e8te \u00e9tait un des facteurs de susceptibilit\u00e9 de l'infection au m\u00eame titre que l'\u00e2ge \u00e9lev\u00e9, l'hypertension art\u00e9rielle, le tabagisme, le surpoids ou l'ob\u00e9sit\u00e9. Ainsi sur une des premi\u00e8res courtes s\u00e9ries \u00e0 Wuhan, ville tr\u00e8s touch\u00e9e par l'\u00e9pid\u00e9mie, sur 41 patients, 20 % \u00e9taient diab\u00e9tiques et 15 % hypertendus [1] . Dans une autre s\u00e9rie sur 140 patients infect\u00e9s et hospitalis\u00e9s, 12 % sont diab\u00e9tiques [2] . L'absence de groupe contr\u00f4le rendait cependant cette possible augmentation de pr\u00e9valence de patients diab\u00e9tiques infect\u00e9s et hospitalis\u00e9s hasardeuse. Par ailleurs, une pr\u00e9valence plus faible de 3 % de diab\u00e9tiques pr\u00e9sentant des sympt\u00f4mes depuis plus de 10 jours est \u00e9galement rapport\u00e9e mais le faible effectif est \u00e0 chaque fois un frein pour estimer correctement cette pr\u00e9valence [3] . Ainsi, dans une m\u00e9ta-analyse reprenant 12 \u00e9tudes en Chine, sur 2018 patients confirm\u00e9s infect\u00e9s, la pr\u00e9valence du diab\u00e8te est de 10,3 % ; elle est finalement du m\u00eame ordre que la pr\u00e9valence des diab\u00e9tiques en Chine en 2013 qui est rapport\u00e9e \u00e0 10,9 % tous \u00e2ges confondus [4, 5] . Maintenant, comme les patients diab\u00e9tiques infect\u00e9s ont en moyenne 49,6 ans, il faut comparer cette pr\u00e9valence \u00e0 celle de la classe d'\u00e2ge correspondante dans la population, estim\u00e9e \u00e0 12,3 % : ainsi la pr\u00e9valence des diab\u00e9tiques parmi les patients atteints de COVID-19 est m\u00eame inf\u00e9rieure \u00e0 celle de la population g\u00e9n\u00e9rale [5] .",
            "cite_spans": [
                {
                    "start": 370,
                    "end": 373,
                    "text": "[1]",
                    "ref_id": "BIBREF0"
                },
                {
                    "start": 462,
                    "end": 465,
                    "text": "[2]",
                    "ref_id": "BIBREF1"
                },
                {
                    "start": 848,
                    "end": 851,
                    "text": "[3]",
                    "ref_id": "BIBREF2"
                },
                {
                    "start": 1124,
                    "end": 1127,
                    "text": "[4,",
                    "ref_id": "BIBREF3"
                },
                {
                    "start": 1128,
                    "end": 1130,
                    "text": "5]",
                    "ref_id": "BIBREF4"
                },
                {
                    "start": 1455,
                    "end": 1458,
                    "text": "[5]",
                    "ref_id": "BIBREF4"
                }
            ],
            "ref_spans": [],
            "section": "Pr\u00e9valence"
        },
        {
            "text": "La m\u00eame tendance est d\u00e9crite en Italie, pays tr\u00e8s touch\u00e9 par le COVID-19. Dans l'\u00e9picentre de l'\u00e9pid\u00e9mie \u00e0 Padoue, 8,9 % des patients infect\u00e9s \u00e2g\u00e9s en moyenne de 65 ans sont diab\u00e9tiques alors que la pr\u00e9valence des diab\u00e9tiques dans cette r\u00e9gion pour la m\u00eame classe d'\u00e2ge est sup\u00e9rieure, d\u00e9crite de 11 % [6] . Ainsi, il n'y aurait peut-\u00eatre pas plus de diab\u00e9tiques repr\u00e9sent\u00e9s chez les patients atteints par le COVID-19 et un patient diab\u00e9tique ne serait pas plus \u00e0 risque de contracter la maladie qu'un non diab\u00e9tique d'apr\u00e8s les donn\u00e9es chinoises et italiennes.",
            "cite_spans": [
                {
                    "start": 302,
                    "end": 305,
                    "text": "[6]",
                    "ref_id": "BIBREF5"
                }
            ],
            "ref_spans": [],
            "section": "Pr\u00e9valence"
        },
        {
            "text": "Aucune \u00e9tude ne permet \u00e0 ce jour de distinguer les diab\u00e9tiques de type 1 et de type 2 mais l'\u00e2ge \u00e9lev\u00e9 des patients atteints plaide pour une forte repr\u00e9sentation des diab\u00e9tiques de type 2. De la m\u00eame fa\u00e7on, la dur\u00e9e d'\u00e9volution du diab\u00e8te, les complications de celui-ci ainsi que le poids des patients dont le r\u00f4le est \u00e9voqu\u00e9 dans la gravit\u00e9 de l'\u00e9volution ne sont pas encore d\u00e9crits. Enfin, les r\u00e9sultats sont difficiles \u00e0 interpr\u00e9ter d\u00e9pendant des crit\u00e8res d'hospitalisation qui \u00e9voluent avec le temps, les formes mod\u00e9r\u00e9es \u00e9tant de moins en moins hospitalis\u00e9es.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Pr\u00e9valence"
        },
        {
            "text": "Si le fait d'\u00eatre diab\u00e9tique n'augmenterait pas la probabilit\u00e9 d'\u00eatre infect\u00e9 par le COVID-19, en revanche, une fois infect\u00e9s, les patients diab\u00e9tiques sont susceptibles d'\u00eatre victimes d'une forme grave de la maladie. Dans une m\u00e9ta-analyse effectu\u00e9e sur 6 \u00e9tudes en Chine, le risque relatif d'avoir une forme grave est de 2,26 (95 % IC : 1,47-3,49) ; il varie depuis 0,31 (moins de risque dans une \u00e9tude) \u00e0 4,06 (plus de risque dans 5 \u00e9tudes) [4] . Par exemple, en Chine dans une \u00e9tude observationnelle sur 1000 patients avec une infection confirm\u00e9e, la pr\u00e9valence du diab\u00e8te chez ceux ayant une forme s\u00e9v\u00e8re est de 16 % et n'est \u00ab que \u00bb de 5,5 % chez ceux ayant une forme moins s\u00e9v\u00e8re [7] . Dans un autre travail cette fois-ci sur 1043 patients italiens infect\u00e9s et hospitalis\u00e9s en Lombardie en unit\u00e9s de soins intensifs (USI), les 2/3 ont une comorbidit\u00e9, 49 % sont hypertendus et 17 % ont un diab\u00e8te [8] . Enfin \u00e0 Seattle, sur 24 patients admis en soins intensifs, 58 % sont diab\u00e9tiques [9] . Les patients diab\u00e9tiques sont \u00e0 risque \u00e9lev\u00e9 de pneumonie s\u00e9v\u00e8re, ont un \u00e9tat pro-inflammatoire et prothrombotique marqu\u00e9 par rapport aux non diab\u00e9tiques infect\u00e9s. Les marqueurs de l'inflammation comme la prot\u00e9ine C r\u00e9active (CRP), l'interleukine 6 la ferritine et les D-dim\u00e8res sont plus \u00e9lev\u00e9s que chez les non diab\u00e9tiques et l'hypoth\u00e8se d'un orage inflammatoire ou cytokinique marqu\u00e9 est \u00e9voqu\u00e9e pour tenter d'expliquer un pronostic plus p\u00e9joratif [10] . Dans une revue et m\u00e9ta-analyse sur 15 \u00e9tudes, 51 845 patients atteints par le COVID-19 dont 9066 sont des cas graves, un \u00e2ge \u00e9lev\u00e9 est ind\u00e9pendamment associ\u00e9 \u00e0 une forme s\u00e9v\u00e8re [11] . Dans cette revue, le diab\u00e8te est aussi associ\u00e9 \u00e0 la survenue d'une forme s\u00e9v\u00e8re avec un RR \u00e0 2,81 (2,01-3,93), et cette association persiste dans une \u00e9tude en analyse multivari\u00e9e prenant en compte l'\u00e2ge, avec un risque relatif \u00e0 2,21 [12] .",
            "cite_spans": [
                {
                    "start": 444,
                    "end": 447,
                    "text": "[4]",
                    "ref_id": "BIBREF3"
                },
                {
                    "start": 687,
                    "end": 690,
                    "text": "[7]",
                    "ref_id": "BIBREF6"
                },
                {
                    "start": 904,
                    "end": 907,
                    "text": "[8]",
                    "ref_id": "BIBREF7"
                },
                {
                    "start": 991,
                    "end": 994,
                    "text": "[9]",
                    "ref_id": "BIBREF8"
                },
                {
                    "start": 1448,
                    "end": 1452,
                    "text": "[10]",
                    "ref_id": "BIBREF9"
                },
                {
                    "start": 1632,
                    "end": 1636,
                    "text": "[11]",
                    "ref_id": "BIBREF10"
                },
                {
                    "start": 1873,
                    "end": 1877,
                    "text": "[12]",
                    "ref_id": "BIBREF11"
                }
            ],
            "ref_spans": [],
            "section": "Diab\u00e8te, COVID-19 et gravit\u00e9 de la maladie"
        },
        {
            "text": "S'il est r\u00e9guli\u00e8rement propos\u00e9 que le risque de forme grave soit augment\u00e9 par la pr\u00e9sence d'un diab\u00e8te d\u00e9s\u00e9quilibr\u00e9 ou compliqu\u00e9, cela repose sur d'autres \u00e9tudes que celles men\u00e9es avec le COVID- L'\u00e9tude CORONADO fran\u00e7aise vise sur l'ensemble du territoire \u00e0 d\u00e9terminer les facteurs pr\u00e9dictifs des formes s\u00e9v\u00e8res [13] .",
            "cite_spans": [
                {
                    "start": 312,
                    "end": 316,
                    "text": "[13]",
                    "ref_id": "BIBREF12"
                }
            ],
            "ref_spans": [],
            "section": "Diab\u00e8te, COVID-19 et gravit\u00e9 de la maladie"
        },
        {
            "text": "J o u r n a l P r e -p r o o f 5 En Chine, les patients en unit\u00e9s de soins intensifs sont plus volontiers diab\u00e9tiques que ceux qui n'y vont pas (22 % vs 6 %) et sans pr\u00e9juger de la pr\u00e9sence d'un diab\u00e8te, sont plus \u00e2g\u00e9s (66 ans vs 51 ans), et ont deux fois plus de comorbidit\u00e9s (72 % vs 37 %) que ceux qui n'y vont pas [14] . Le sexe masculin qui semble pr\u00e9dominer chez les patients infect\u00e9s avec une proportion d\u00e9crite allant de 56 % jusqu'\u00e0 82 % semble aussi sur-repr\u00e9sent\u00e9 chez ceux en unit\u00e9s de soins intensifs [61 % vs 52 %] mais cette diff\u00e9rence n'est pas significative [3, 8, 14] .",
            "cite_spans": [
                {
                    "start": 318,
                    "end": 322,
                    "text": "[14]",
                    "ref_id": "BIBREF13"
                },
                {
                    "start": 575,
                    "end": 578,
                    "text": "[3,",
                    "ref_id": "BIBREF2"
                },
                {
                    "start": 579,
                    "end": 581,
                    "text": "8,",
                    "ref_id": "BIBREF7"
                },
                {
                    "start": 582,
                    "end": 585,
                    "text": "14]",
                    "ref_id": "BIBREF13"
                }
            ],
            "ref_spans": [],
            "section": "Quels types de patients sont en soins intensifs ?"
        },
        {
            "text": "Parmi 44 672 patients infect\u00e9s, le taux de mortalit\u00e9 rapport\u00e9 en Chine est de 2,3 % ; il est de 7,3 % en pr\u00e9sence d'un diab\u00e8te et de 6 % chez les hypertendus [15] . En Italie, parmi les patients d\u00e9c\u00e9d\u00e9s, 35 % d'entre eux sont diab\u00e9tiques contre 20 % dans la population g\u00e9n\u00e9rale pour cette tranche d'\u00e2ge :",
            "cite_spans": [
                {
                    "start": 158,
                    "end": 162,
                    "text": "[15]",
                    "ref_id": "BIBREF14"
                }
            ],
            "ref_spans": [],
            "section": "Diab\u00e8te et d\u00e9c\u00e8s"
        },
        {
            "text": "les diab\u00e9tiques sont donc surrepr\u00e9sent\u00e9s parmi les patients d\u00e9c\u00e9d\u00e9s ; 70 % sont des hommes \u00e2g\u00e9s en moyenne de 80 ans [4] .",
            "cite_spans": [
                {
                    "start": 117,
                    "end": 120,
                    "text": "[4]",
                    "ref_id": "BIBREF3"
                }
            ],
            "ref_spans": [],
            "section": "Diab\u00e8te et d\u00e9c\u00e8s"
        },
        {
            "text": "Nous n'aborderons pas ici l'intrication entre diab\u00e8te et hypertension art\u00e9rielle et la gestion des inhibiteurs du syst\u00e8me r\u00e9nine-angiotensine d\u00e9j\u00e0 trait\u00e9e [16] . Nous rappelons seulement qu'en dehors d'une situation aigue o\u00f9 une attitude au cas par cas est de rigueur, la Soci\u00e9t\u00e9 europ\u00e9enne de cardiologie a publi\u00e9 une prise de position pour maintenir les traitements par inhibiteurs de l'enzyme de conversion (IEC) ou sartans.",
            "cite_spans": [
                {
                    "start": 155,
                    "end": 159,
                    "text": "[16]",
                    "ref_id": "BIBREF15"
                }
            ],
            "ref_spans": [],
            "section": "M\u00e9dicaments et diab\u00e8te"
        },
        {
            "text": "De la m\u00eame fa\u00e7on, nous nous bornons \u00e0 souligner que les cortico\u00efdes ont probablement un r\u00f4le d\u00e9l\u00e9t\u00e8re mais l'analyse r\u00e9trospective est difficile car ils sont g\u00e9n\u00e9ralement utilis\u00e9s dans les cas (tr\u00e8s) graves et que les anti-inflammatoires non st\u00e9ro\u00efdiens comme l'ibuprof\u00e8ne augmenteraient le risque de forme grave comme cela avait d\u00e9j\u00e0 \u00e9t\u00e9 rappel\u00e9 par l'Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9 (ANSM) dans le pass\u00e9 pour d'autres infections. Ainsi, la fi\u00e8vre doit \u00eatre trait\u00e9e uniquement par du parac\u00e9tamol [17, 18] .",
            "cite_spans": [
                {
                    "start": 533,
                    "end": 537,
                    "text": "[17,",
                    "ref_id": "BIBREF16"
                },
                {
                    "start": 538,
                    "end": 541,
                    "text": "18]",
                    "ref_id": "BIBREF17"
                }
            ],
            "ref_spans": [],
            "section": "M\u00e9dicaments et diab\u00e8te"
        },
        {
            "text": "Concernant les m\u00e9dicaments sp\u00e9cifiques du diab\u00e8te de type 2, la question d'une augmentation du risque infectieux se pose avec les inhibiteurs de la dipeptidyl peptidase-4 (iDPP-4). En effet, outre son r\u00f4le dans le m\u00e9tabolisme des incr\u00e9tines et la r\u00e9gulation du glucose, la DPP-4, aussi appel\u00e9e CD26, est une glycoprot\u00e9ine membranaire pr\u00e9sente \u00e0 la surface de nombreuses cellules pr\u00e9sentant une activit\u00e9 enzymatique exopeptidase non sp\u00e9cifique. Elle stimule les r\u00e9ponses immunitaires inflammatoires en modifiant la production de plusieurs cytokines et ch\u00e9mokines [19] [20] [21] [22] . Ainsi, plusieurs \u00e9tudes ont concern\u00e9 le r\u00f4le des inhibiteurs de la DPP-4 dans la survenue d'infections. Les donn\u00e9es des essais cliniques sugg\u00e9raient une augmentation des infections respiratoires hautes et urinaires basses avec les iDDP-4, en particulier avec la sitaglitpine [23, 24] . L'analyse de la base de donn\u00e9es internationale de pharmacovigilance VigiBase indiquait une plus forte d\u00e9claration d'infections avec les iDDP-4 avec un signal plus important pour les infections respiratoires hautes [25] mais une \u00e9tude cas-t\u00e9moin nich\u00e9e dans une cohorte de pr\u00e8s de 50 000 patients diab\u00e9tiques enregistr\u00e9s dans la base de donn\u00e9es Clinical Practice Research Database (CPRD) au Royaume-Uni ne retrouvait pas de lien entre l'utilisation d'iDDP-4 et l'hospitalisation pour pneumonie communautaire [26] , et la m\u00e9ta-analyse la plus r\u00e9cente incluant 74 essais cliniques de plus de 12 semaines ne sugg\u00e9rait pas non plus d'augmentation du risque global d'infection avec les iDDP-4 [27] .",
            "cite_spans": [
                {
                    "start": 562,
                    "end": 566,
                    "text": "[19]",
                    "ref_id": "BIBREF18"
                },
                {
                    "start": 567,
                    "end": 571,
                    "text": "[20]",
                    "ref_id": "BIBREF20"
                },
                {
                    "start": 572,
                    "end": 576,
                    "text": "[21]",
                    "ref_id": "BIBREF21"
                },
                {
                    "start": 577,
                    "end": 581,
                    "text": "[22]",
                    "ref_id": "BIBREF22"
                },
                {
                    "start": 859,
                    "end": 863,
                    "text": "[23,",
                    "ref_id": null
                },
                {
                    "start": 864,
                    "end": 867,
                    "text": "24]",
                    "ref_id": "BIBREF25"
                },
                {
                    "start": 1084,
                    "end": 1088,
                    "text": "[25]",
                    "ref_id": "BIBREF26"
                },
                {
                    "start": 1377,
                    "end": 1381,
                    "text": "[26]",
                    "ref_id": "BIBREF27"
                },
                {
                    "start": 1557,
                    "end": 1561,
                    "text": "[27]",
                    "ref_id": "BIBREF29"
                }
            ],
            "ref_spans": [],
            "section": "M\u00e9dicaments et diab\u00e8te"
        },
        {
            "text": "Chez des patients diab\u00e9tiques, la sitaglipitne r\u00e9duirait les niveaux de marqueurs proinflammatoires tels que l'interleukine-6 (IL-6) et le tumor necrosis factor-\u03b1 (TNF-\u03b1) [28, 29] . Les iDPP-4 pourraient ainsi, via cet effet anti-inflammatoire, jouer un r\u00f4le au d\u00e9cours de l'infection ou dans la survenue de ses complications. Il est actuellement montr\u00e9 que, chez les patients atteints de COVID-19, des taux d'IL-6 significativement \u00e9lev\u00e9s sont associ\u00e9s \u00e0 un risque accru de d\u00e9compensation respiratoire [30, 31] .",
            "cite_spans": [
                {
                    "start": 171,
                    "end": 175,
                    "text": "[28,",
                    "ref_id": "BIBREF30"
                },
                {
                    "start": 176,
                    "end": 179,
                    "text": "29]",
                    "ref_id": "BIBREF31"
                },
                {
                    "start": 503,
                    "end": 507,
                    "text": "[30,",
                    "ref_id": "BIBREF32"
                },
                {
                    "start": 508,
                    "end": 511,
                    "text": "31]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "M\u00e9dicaments et diab\u00e8te"
        },
        {
            "text": "Il est par ailleurs int\u00e9ressant de noter que la DPP-4 humaine a \u00e9t\u00e9 identifi\u00e9e comme un r\u00e9cepteur fonctionnel pour la prot\u00e9ine de spicule du coronavirus responsable du Middle East Respiratory Syndrome (MERS) en Arabie Saoudite en 2012 [32] . Les anticorps dirig\u00e9s contre la DPP-4 exer\u00e7aient une action inhibitrice sur l'infection par le MERS-CoV. Les \u00e9tudes sur souris transg\u00e9niques sugg\u00e9raient que le taux de complications chez les personnes atteintes de diab\u00e8te de type 2 infect\u00e9es par le MERS-CoV pourrait \u00eatre associ\u00e9 \u00e0 une perturbation de la r\u00e9ponse immunitaire par la DPP4 [33] . Sans que l'on puisse \u00e0 ce jour en tirer des cons\u00e9quences directes pour l'\u00e9pid\u00e9mie actuelle de COVID-19 (dont la porte d'entr\u00e9e est l'enzyme de conversion de l'angiotensine 2 ",
            "cite_spans": [
                {
                    "start": 235,
                    "end": 239,
                    "text": "[32]",
                    "ref_id": "BIBREF35"
                },
                {
                    "start": 579,
                    "end": 583,
                    "text": "[33]",
                    "ref_id": "BIBREF36"
                }
            ],
            "ref_spans": [],
            "section": "M\u00e9dicaments et diab\u00e8te"
        },
        {
            "text": "La Soci\u00e9t\u00e9 fran\u00e7aise de diab\u00e9tologie s'est tr\u00e8s t\u00f4t saisie des modalit\u00e9s de gestion du diab\u00e8te au quotidien en situation de crise COVID sans distinguer la prise en charge du diab\u00e8te de type 1 ou 2 mais prodiguant des conseils qui s'appliquent dans les deux situations. Ainsi, parmi 10 messages clefs, il est soulign\u00e9 le sur-risque de formes graves chez les patients diab\u00e9tiques avec comorbidit\u00e9s, l'importance des mesures barri\u00e8res, l'int\u00e9r\u00eat de pr\u00e9voir un stock de m\u00e9dicaments et capteurs pour 2 semaines et le risque d'acidoc\u00e9tose major\u00e9 chez le diab\u00e9tique de type 1 [34] .",
            "cite_spans": [
                {
                    "start": 569,
                    "end": 573,
                    "text": "[34]",
                    "ref_id": "BIBREF37"
                }
            ],
            "ref_spans": [],
            "section": "Que disent les recommandations ?"
        },
        {
            "text": "Pour aider les r\u00e9animateurs, des fiches pratiques de gestion des diab\u00e9tiques dans ces unit\u00e9s sont \u00e9labor\u00e9es et celles-ci ne sont pas exclusives de l'infection virale COVID-19 et ressemblent aux pr\u00e9conisations de gestion dans la p\u00e9riode p\u00e9ri-op\u00e9ratoire [35] . Elles ont aussi pour but de standardiser la prise en charge en \u00e9vitant les hyperglyc\u00e9mies qui pourraient \u00eatre d\u00e9l\u00e9t\u00e8res dans ce contexte infectieux mais aussi les hypoglyc\u00e9mies dont l'impact n\u00e9gatif lors d'une cardiopathie isch\u00e9mique notamment est r\u00e9guli\u00e8rement rappel\u00e9. Il est ainsi signal\u00e9 qu'une insulinor\u00e9sistance initiale est observ\u00e9e, qu'une insulinoth\u00e9rapie en intra veineuse \u00e0 la seringue \u00e9lectrique (IVSE) est conseill\u00e9e avec fixation d'objectifs glyc\u00e9miques, que les traitements non insuliniques du diab\u00e8te de type 2 doivent \u00eatre arr\u00eat\u00e9s et la reprise ult\u00e9rieure conditionn\u00e9e par l'\u00e9tat clinique du patient (fonction r\u00e9nale, cardiaque, respiratoire). \u00c0 l'inverse, l'insuline ne doit jamais \u00eatre arr\u00eat\u00e9e chez les patients diab\u00e9tiques de type 1 chez qui le risque d'acidoc\u00e9tose augmente dans ce contexte. La surveillance de la glyc\u00e9mie sera r\u00e9alis\u00e9e avec des glyc\u00e9mies classiques (sang art\u00e9riel > veineux > capillaire), les capteurs de",
            "cite_spans": [
                {
                    "start": 252,
                    "end": 256,
                    "text": "[35]",
                    "ref_id": "BIBREF38"
                }
            ],
            "ref_spans": [],
            "section": "Que disent les recommandations ?"
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China",
            "authors": [
                {
                    "first": "C",
                    "middle": [],
                    "last": "Huang",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Ren",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Zhao",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Hu",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Lancet",
            "volume": "395",
            "issn": "",
            "pages": "497--506",
            "other_ids": {}
        },
        "BIBREF1": {
            "ref_id": "b1",
            "title": "Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "J"
                    ],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Dong",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [
                        "Y"
                    ],
                    "last": "Cao",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [
                        "D"
                    ],
                    "last": "Yuan",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [
                        "B"
                    ],
                    "last": "Yang",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [
                        "Q"
                    ],
                    "last": "Yan",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "China. Allergy",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1111/all.14238"
                ]
            }
        },
        "BIBREF2": {
            "ref_id": "b2",
            "title": "Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series",
            "authors": [
                {
                    "first": "X",
                    "middle": [
                        "W"
                    ],
                    "last": "Xu",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [
                        "X"
                    ],
                    "last": "Wu",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [
                        "G"
                    ],
                    "last": "Jiang",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "J"
                    ],
                    "last": "Xu",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [
                        "J"
                    ],
                    "last": "Ying",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "L"
                    ],
                    "last": "Ma",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "BMJ",
            "volume": "368",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF3": {
            "ref_id": "b3",
            "title": "Prevalence and impact of diabetes among people infected with SARS-CoV-2",
            "authors": [
                {
                    "first": "G",
                    "middle": [
                        "P"
                    ],
                    "last": "Fadini",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "L"
                    ],
                    "last": "Morieri",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Longato",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Avogaro",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J Endocrinol Invest",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1007/s40618-020-01236-2"
                ]
            }
        },
        "BIBREF4": {
            "ref_id": "b4",
            "title": "Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013",
            "authors": [
                {
                    "first": "L",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Gao",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Huang",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "Q",
                    "middle": [],
                    "last": "Deng",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "JAMA",
            "volume": "317",
            "issn": "",
            "pages": "2515--2538",
            "other_ids": {}
        },
        "BIBREF5": {
            "ref_id": "b5",
            "title": "Diabetes diagnosis from administrative claims and estimation of the true prevalence of diabetes among 4.2 million individuals of the Veneto region",
            "authors": [
                {
                    "first": "E",
                    "middle": [],
                    "last": "Longato",
                    "suffix": ""
                },
                {
                    "first": "Di",
                    "middle": [],
                    "last": "Camillo",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Sparacino",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Saccavini",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Avogaro",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Fadini",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [
                        "P"
                    ],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Nutr Metab Cardiovasc Dis",
            "volume": "30",
            "issn": "",
            "pages": "84--91",
            "other_ids": {}
        },
        "BIBREF6": {
            "ref_id": "b6",
            "title": "Clinical characteristics of coronavirus disease 2019 in China",
            "authors": [
                {
                    "first": "W",
                    "middle": [
                        "J"
                    ],
                    "last": "Guan",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [
                        "Y"
                    ],
                    "last": "Ni",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Hu",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [
                        "H"
                    ],
                    "last": "Liang",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "Q"
                    ],
                    "last": "Ou",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "X"
                    ],
                    "last": "He",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "N Engl J Med",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1056/NEJMoa2002032"
                ]
            }
        },
        "BIBREF7": {
            "ref_id": "b7",
            "title": "Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region",
            "authors": [
                {
                    "first": "G",
                    "middle": [],
                    "last": "Grasselli",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Zangrillo",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Zanella",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Antonelli",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Cabrini",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Castello",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "JAMA",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1001/jama.2020.5394"
                ]
            }
        },
        "BIBREF8": {
            "ref_id": "b8",
            "title": "Covid-19 in critically ill patients in the Seattle region -Case series",
            "authors": [
                {
                    "first": "P",
                    "middle": [
                        "K"
                    ],
                    "last": "Bhatraju",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [
                        "J"
                    ],
                    "last": "Ghassemieh",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Nichols",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Kim",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "R"
                    ],
                    "last": "Jerome",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "K"
                    ],
                    "last": "Nalla",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "N Engl J Med",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1056/NEJMoa2004500"
                ]
            }
        },
        "BIBREF9": {
            "ref_id": "b9",
            "title": "Diabetes is a risk factor for the progression and prognosis of COVID-19",
            "authors": [
                {
                    "first": "W",
                    "middle": [],
                    "last": "Guo",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Dong",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Zhou",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Tian",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Diabetes Metab Res Rev",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1002/dmrr.3319"
                ]
            }
        },
        "BIBREF10": {
            "ref_id": "b10",
            "title": "The relationship of COVID-19 severity with cardiovascular disease and its traditional risk factors: A systematic review and metaanalysis",
            "authors": [
                {
                    "first": "K",
                    "middle": [],
                    "last": "Matsushita",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Ding",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Kou",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Hu",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Gao",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "2020",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1101/2020.04.05.20054155"
                ]
            }
        },
        "BIBREF11": {
            "ref_id": "b11",
            "title": "Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China",
            "authors": [
                {
                    "first": "W",
                    "middle": [],
                    "last": "Liang",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Weijie",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Xu",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Lancet Oncol",
            "volume": "21",
            "issn": "3",
            "pages": "335--342",
            "other_ids": {}
        },
        "BIBREF12": {
            "ref_id": "b12",
            "title": "CORONAvirus disease 2019 and Diabetes Outcomes",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Soci\u00e9t\u00e9 Francophone Du Diab\u00e8te. L&apos;\u00e9tude",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Coronado",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF13": {
            "ref_id": "b13",
            "title": "Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China",
            "authors": [
                {
                    "first": "D",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Hu",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Hu",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Zhu",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "JAMA",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1001/jama.2020.1585"
                ]
            }
        },
        "BIBREF14": {
            "ref_id": "b14",
            "title": "Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention",
            "authors": [
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Wu",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "M"
                    ],
                    "last": "Mcgoogan",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "2020",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1001/jama.2020.2648"
                ]
            }
        },
        "BIBREF15": {
            "ref_id": "b15",
            "title": "Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. IEC ARA2 et COVID19",
            "authors": [],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF16": {
            "ref_id": "b16",
            "title": "ANSM. Anti-inflammatoires non st\u00e9ro\u00efdiens (AINS) et complications infectieuses graves -Point d'information. Avril",
            "authors": [],
            "year": 2019,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF17": {
            "ref_id": "b17",
            "title": "R\u00e9ponses d'experts \u00e0 vos questions sur les m\u00e9dicaments et le COVID-19",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Soci\u00e9t\u00e9 Fran\u00e7aise De Pharmacologie",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "De Th\u00e9rapeutique",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF18": {
            "ref_id": "b18",
            "title": "Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides",
            "authors": [
                {
                    "first": "R",
                    "middle": [],
                    "last": "Mentlein",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF20": {
            "ref_id": "b20",
            "title": "Implications of DPP4 modification of proteins that regulate stem/progenitor and more mature cell types",
            "authors": [
                {
                    "first": "X",
                    "middle": [],
                    "last": "Ou",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [
                        "A"
                    ],
                    "last": "O&apos;leary",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [
                        "E"
                    ],
                    "last": "Broxmeyer",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Blood",
            "volume": "122",
            "issn": "",
            "pages": "161--170",
            "other_ids": {}
        },
        "BIBREF21": {
            "ref_id": "b21",
            "title": "Dual inhibition of dipeptidyl peptidase IV and aminopeptidase N suppresses inflammatory immune responses",
            "authors": [
                {
                    "first": "D",
                    "middle": [],
                    "last": "Reinhold",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Biton",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Goihl",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Pieper",
                    "suffix": ""
                },
                {
                    "first": "U",
                    "middle": [],
                    "last": "Lendeckel",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Faust",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "Ann N Y Acad Sci",
            "volume": "1110",
            "issn": "",
            "pages": "402--411",
            "other_ids": {}
        },
        "BIBREF22": {
            "ref_id": "b22",
            "title": "Targeting dipeptidyl peptidase IV (CD26) suppresses autoimmune encephalomyelitis and up-regulates TGFbeta 1 secretion in vivo",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Steinbrecher",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Reinhold",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Quigley",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Gado",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Tresser",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Izikson",
                    "suffix": ""
                }
            ],
            "year": 2001,
            "venue": "J Immunol",
            "volume": "166",
            "issn": "",
            "pages": "2041--2049",
            "other_ids": {}
        },
        "BIBREF24": {
            "ref_id": "b24",
            "title": "inhibitors for type 2 diabetes mellitus",
            "authors": [],
            "year": 2008,
            "venue": "Cochrane Database Syst Rev",
            "volume": "006739",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1002/14651858.CD006739.pub2"
                ]
            }
        },
        "BIBREF25": {
            "ref_id": "b25",
            "title": "Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Monami",
                    "suffix": ""
                },
                {
                    "first": "I",
                    "middle": [],
                    "last": "Iacomelli",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Marchionni",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Mannucci",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "Nutr Metab Cardiovasc Dis",
            "volume": "20",
            "issn": "",
            "pages": "224--259",
            "other_ids": {}
        },
        "BIBREF26": {
            "ref_id": "b26",
            "title": "Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "J"
                    ],
                    "last": "Willemen",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "K"
                    ],
                    "last": "Mantel-Teeuwisse",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "M"
                    ],
                    "last": "Straus",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "H"
                    ],
                    "last": "Meyboom",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [
                        "C"
                    ],
                    "last": "Egberts",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [
                        "G"
                    ],
                    "last": "Leufkens",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "Diabetes Care",
            "volume": "34",
            "issn": "",
            "pages": "369--74",
            "other_ids": {}
        },
        "BIBREF27": {
            "ref_id": "b27",
            "title": "DPP-4 inhibitors and the risk of community-acquired pneumonia in patients with type 2 diabetes",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "L"
                    ],
                    "last": "Faillie",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "B"
                    ],
                    "last": "Filion",
                    "suffix": ""
                },
                {
                    "first": "V",
                    "middle": [],
                    "last": "Patenaude",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Ernst",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Azoulay",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "Diabetes Obes Metab",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF29": {
            "ref_id": "b29",
            "title": "DPP-4 inhibitors and risk of infections: a meta-analysis of randomized controlled trials",
            "authors": [
                {
                    "first": "W",
                    "middle": [],
                    "last": "Yang",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Cai",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Han",
                    "suffix": ""
                },
                {
                    "first": "Ji",
                    "middle": [
                        "L"
                    ],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "Diabetes Metab Res Rev",
            "volume": "32",
            "issn": "",
            "pages": "391--404",
            "other_ids": {}
        },
        "BIBREF30": {
            "ref_id": "b30",
            "title": "A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients",
            "authors": [
                {
                    "first": "N",
                    "middle": [],
                    "last": "Satoh-Asahara",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Sasaki",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Wada",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Tochiya",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Iguchi",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Nakagawachi",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Metabolism",
            "volume": "62",
            "issn": "",
            "pages": "347--51",
            "other_ids": {}
        },
        "BIBREF31": {
            "ref_id": "b31",
            "title": "Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its antiinflammatory effects in patients with coronary artery disease and uncontrolled diabetes",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Matsubara",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Sugiyama",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Akiyama",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Iwashita",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Kurokawa",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Ohba",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Circ J",
            "volume": "77",
            "issn": "",
            "pages": "1337--1381",
            "other_ids": {}
        },
        "BIBREF32": {
            "ref_id": "b32",
            "title": "Interleukin-6 in COVID-19: a systematic review and metaanalysis",
            "authors": [
                {
                    "first": "E",
                    "middle": [
                        "A"
                    ],
                    "last": "Coomes",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Haghbayan",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "2020",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1101/2020.03.30.20048058"
                ]
            }
        },
        "BIBREF34": {
            "ref_id": "b34",
            "title": "Level of IL-6 predicts respiratory failure in hospitalized symptomatic COVID-19 patients",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "2020",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1101/2020.04.01.20047381"
                ]
            }
        },
        "BIBREF35": {
            "ref_id": "b35",
            "title": "Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC",
            "authors": [
                {
                    "first": "V",
                    "middle": [
                        "S"
                    ],
                    "last": "Raj",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Mou",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "L"
                    ],
                    "last": "Smits",
                    "suffix": ""
                },
                {
                    "first": "Dhw",
                    "middle": [],
                    "last": "Dekkers",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "A"
                    ],
                    "last": "M\u00fcller",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Dijkman",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Nature",
            "volume": "495",
            "issn": "",
            "pages": "251--255",
            "other_ids": {}
        },
        "BIBREF36": {
            "ref_id": "b36",
            "title": "COVID-19 and diabetes: can DPP4 inhibition play a role?",
            "authors": [
                {
                    "first": "G",
                    "middle": [],
                    "last": "Iacobellis",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Diabetes Res Clin Pract",
            "volume": "162",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF37": {
            "ref_id": "b37",
            "title": "Diab\u00e8te et COVID-19 : 10 messages cl\u00e9s",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Soci\u00e9t\u00e9 Francophone Du Diab\u00e8te",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "2020",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF38": {
            "ref_id": "b38",
            "title": "Prise en charge des patients diab\u00e9tiques \u00e0 la phase aigu\u00eb d'une infection, en r\u00e9animation",
            "authors": [],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        }
    },
    "ref_entries": {
        "FIGREF0": {
            "text": "19 qui retra\u00e7aient le sur-risque des patients diab\u00e9tiques avec les virus H1N1 en 2009 et avec Middle East Respiratory Syndrome Coronavirus (MERS-CoV) en 2012[13][14][15].",
            "latex": null,
            "type": "figure"
        },
        "FIGREF1": {
            "text": "ACE2]), l'\u00e9tude des liens entre DPP-4 et infection \u00e0 coronavirus m\u00e9rite d'\u00eatre poursuivie. Que nous apprennent les donn\u00e9es de pharmacovigilance en France ? Le r\u00e9seau national des centres de pharmacovigilance surveille quotidiennement les effets ind\u00e9sirables des m\u00e9dicaments utilis\u00e9s dans le cadre du COVID-19. Au 17 avril 2020, il \u00e9tait d\u00e9clar\u00e9 47 cas d'effet ind\u00e9sirable m\u00e9dicamenteux survenus dans un contexte d'infection \u00e0 COVID-19 chez des patients pr\u00e9sentant un diab\u00e8te. L'\u00e2ge m\u00e9dian des patients \u00e9tait de 67 ans (min-max : 34-88 ans), 66 % \u00e9taient des hommes, 85 % (n = 40) des cas \u00e9taient graves et 7 (14 %) sont d\u00e9c\u00e9d\u00e9s. Un tiers de ces cas (16 patients) ont pr\u00e9sent\u00e9 des troubles du rythme cardiaque en lien principalement \u00e0 l'utilisation d'hydroxychloroquine associ\u00e9 ou non \u00e0 l'azithromycine. Parmi ces derniers, 94 % pr\u00e9sentaient une hypertension art\u00e9rielle et 38 % un ant\u00e9c\u00e9dent cardiaque. Huit cas (hypertendus et 18 % avaient des ant\u00e9c\u00e9dents pulmonaires). Parmi ces cas, 4 patients trait\u00e9s au long cours par sitagliptine ont n\u00e9cessit\u00e9 une prise en charge en r\u00e9animation (un cas est d\u00e9c\u00e9d\u00e9). Il s'agit de 3 femmes et 1 homme, de 65 \u00e0 88 ans, deux \u00e9taient ob\u00e8ses, tous \u00e9taient hypertendus. Dans aucun cas, la sitagliptine n'\u00e9tait le seul m\u00e9dicament suspect d'aggravation de l'infection : 2 cas \u00e9taient \u00e9galement trait\u00e9s avec un sartan et 2 avaient re\u00e7u un anti-inflammatoire non st\u00e9ro\u00efdien (AINS).",
            "latex": null,
            "type": "figure"
        }
    },
    "back_matter": []
}